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A B S T R A C TObjective: Therapies for end-stage renal disease improve quality of
life, and survival. In Mexico, clinicians often must choose between
different therapies without the availability of comparative outcomes
evaluation. The present study evaluates the comparative cost-utility
of sirolimus (SIR) versus tacrolimus (TAC) for the primary prevention
of graft rejection in renal transplant recipients in Mexico. Methods:
We used modeling techniques to estimate the cost-effectiveness of
SIR versus TAC to prevent graft rejection in patients with end-stage
renal disease in the Mexican setting. The model estimates the cost
of quality-adjusted life-year (QALY) per patient. We applied a 20-year
horizon (1-year Markov cycles). Cost-effectiveness was expressed in
terms of cost per QALY. All costs are presented in 2011 US dollars.
Probabilistic sensitivity analyses were conducted. Results: The total
cost for the SIR treatment arm over the 20-year duration of the model
is estimated to be $136,778. This compares with $142,624 for the TAC
treatment arm, resulting in an incremental cost of SIR compared withnt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.09.013
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ondence to: Kely Rely, CEAHealthTech, Repu´blicas 1that of TAC of $5,846. Over 20 years, SIR was estimated to have 8.18
QALYs compared with 7.33 QALYs for TAC. The resulting incremental
utility of SIR compared with that of TAC is 0.84 QALY gained. SIR is
estimated to be both less costly and more effective than TAC,
indicating that it is the dominant strategy. Notably, results suggest
that SIR has a 78% probability of being dominant over the TAC strategy
and a 100% probability of having an incremental cost-effectiveness
ratio at or below $10,064 (1 GDP) per QALY. Conclusions: These
analyses suggest that in the Mexican setting, the use of SIR in place
of TAC for the prevention of graft rejection in this population is likely
to be cost saving.
Keywords: cost-effectiveness, immunosuppression, Markov model,
renal transplant, sirolimus.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The worldwide rise in the number of patients with chronic renal
disease and subsequent end-stage renal disease (ESRD) is threaten-
ing to reach epidemic magnitudes over the next decades [1,2].
In Mexico, ESRD is a major complication of diabetes and requires
dialysis or transplantation for survival. It is estimated that there are
175,729 persons in Mexico with type 2 diabetes and nephropathy
(urine albumin/creatinine4 300 mg/g) [3]. During the last decade,
Mexico has experienced growth in its dialysis population. Approxi-
mately 25,000 patients currently receive chronic dialysis, with the
majority receiving continuous ambulatory peritoneal dialysis [4].
Renal transplantation is the treatment of choice for ESRD
because, if successful, the quality and duration of life is better
than that achieved with long-term dialysis [5–9]. ESRD has not
only clinical consequences but also economic implications.
Prolonged dialysis and subsequent retransplantation are asso-
ciated with increased direct and indirect costs that affect both
society and individual patients. Total annual costs of treating
ESRD patients in Mexico were estimated at US $24,032 per patientand US $15,724 per patient for hemodialysis and peritoneal
dialysis, respectively [10].
Immunosuppressive drugs have been widely used in renal
transplantation, providing low rates of rejection and improved
graft survival over earlier regimens [11–13]. Their long-term use is
associated with impaired renal function and an increase in
cardiovascular risk factors, although some of these risk factors
lead to progressive renal dysfunction [14].
Sirolimus (SIR), which does not have the adverse events asso-
ciated with calcineurin inhibitors (CNIs), has recently become avail-
able for prophylaxis of organ rejection in patients at mild to
moderate immunological risk receiving renal transplants [15]. SIR
reduced the incidence of subsequent acute rejection episodes and
the need for additional drug therapy in patients experiencing acute
rejection. Unlike CNIs, SIR is not nephrotoxic [16–18] and therefore
offers the prospect of improved longer term graft survival while
maintaining the improvements in short-term outcomes delivered to
date by cyclosporine A (CsA) and tacrolimus (TAC) [19–24]. Convert-
ing patients to SIR earlier, when serum creatinine is lower, leads to
significantly greater improvements in renal function [25,26].for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Costs of medications for each treatment arm and
the costs of ESRD treatment [38,39].
Costs of
medications
Drugs Doses Cost/
day
–Steroid Prednisone 0,5 mg/kg/d $ 0.28
–Calcineurin
inhibitors
Cyclosporine 8–10 mg/kg/d $ 3
Tacro´limus 0,15–0.30 mg/
kg/d
$ 13
–mTOR inhibitors Siro´limus 2–5 mg/d $ 11
Medical cost
–Functioning graft $ 6,844
–Acute rejection $ 5,734
–Dialysis $ 10,709
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the financial constraints in the Mexican health care system, efficient
allocation of scarce resources becomes increasingly important.
The objective of this study was to conduct a computerized
cost-effectiveness analysis of SIR versus TAC for the treatment of
ESRD. Outcomes and costs were combined to assess the com-
parative cost-effectiveness of treatment with SIR or TAC for the
prevention of graft rejection in renal transplant recipients. Mathe-
matic models were used to assess the comparative effectiveness
and cost-effectiveness of alternative treatment strategies. The
study results may be used to guide policy decisions, to inform
clinicians, or to assist in the design of future clinical studies.
Methods
A cost-utility analysis was conducted by using a Markov model
[27,28] to compare SIR with TAC in the prophylaxis of organ
rejection in renal transplant recipients. The population entering
the model was assumed to be 40 years of age. These assumptions
were based on the average age and weight of patients in the trial
(concurrent once-daily versus twice-daily radio therapy (CONVERT)
[29] and CONCEPT [30]). The model was constructed, simulating the
natural history of patient with renal transplantation, with four
mutually exclusive disease states: rejection free, acute rejection,
graft loss, and death. The cycle length for the model was set to 3
months to fully incorporate the effect of therapy on quality of life,
and the maximum time horizon was set to 20 years.
The model considers 1) an initial therapy; this is given to all
recipients, except where the donor is an identical twin, at the
outset of treatment. Therapy is usually triple therapy, using
one specific CNI (i.e., CsA or TAC) in combination with a steroidcFunctional 
uFunctional 
death
 
Functioning graft 
Functioning graft with 
acute rejection 
uFails
cFails 
Dialysis 
cDialysis 
uDialysis 
Fig. 1 – Model structure.(e.g., prednisolone) and azathioprine, and 2) maintenance ther-
apy; this is the immunosuppression on which patients are
maintained long term, essentially the entire duration of the
survival of the kidney graft. Often, maintenance therapy is
identical to initial therapy, but at a reduced dosage because the
transplanted kidney becomes immunologically more stable with
increasing time. [31] It is also not uncommon, however, for agents
used in maintenance therapy to be altered in response to side
effects or the development of acute rejection or chronic allograft
nephropathy [32]. The costs of long-term maintenance therapy
were included because the analysis was limited to 20 years.
Model Structure
The model, presented in Figure 1, is a Markov-based model and is
programmed in Microsoft Excel 2010. The model begins with the
choice of immunosuppressive therapies following the initiation of
prophylaxis. Model health states included functioning graft, func-
tioning graft with acute rejection, graft loss (dialysis), dialysis, and
death. Patients could transition back and forth from functioning
graft and functioning graft with acute rejection in the Markov
portion of the model. Patients in either of these states could
transition to graft loss (dialysis) upon beginning dialysis treatment.
Patients could enter the death state from any model state, including
the model permitting death with graft function, at any cycle.
Input Parameters
The model considers various parameters to estimate total costs, life
years, and quality-adjusted life-years (QALYs). Input parameters
were taken from a variety of sources including clinical trial data and
other published studies [29,30,33–36]. Input parameters such as
mortality and clinical efficacy (acute rejection, graft loss, dialysis)
were extracted from a variety of sources [9]. Efficacy for treatment
regimens was measured as the difference in the risk of acute
rejection, graft loss, dialysis, and death between regimens. Disease
progression data were derived from a critical review of the litera-
ture, previous cost-effectiveness analyses, and an ESRD natural
history model recently presented by Morton et al. [37].
Costs of Treatment
The cost of treating an ERSD in Mexico was obtained from an
economic evaluation ‘‘Cost-effectiveness of interventions for end-
stage renal disease.’’ The authors used a cost-effectiveness model to
estimate the direct medical costs associated with treating an ESRD.
The estimate includes costs of inpatient and outpatient care, mon-
itoring for side effects, prophylaxis, and treatment of side effects and
is expressed in 1998 Mexican pesos. Costs were updated to US dollars
in 2011 by using the consumer price index for medical care (Table 1).
Direct medical costs were calculated as the sum of treatment
costs, drugs cost, patient management costs, and the cost of
complications (visits, hospitalizations, emergency consults, labora-
tory tests, diagnosis tests, etc.).
Utility Weights
Utility weights were applied from those previously used in an
ESRD decision model. These utility values are used to estimate
QALYs by multiplying the number of life years within a particular
health state by the health state’s utility weight. Utility weights by
disease severity were obtained from a study by Laupacis et al. [40]
in which 0.76 was estimated for a graft functioning, 0.68 for graft
loss, and 0.54 for dialysis.
Discounting, Time Horizon, and Perspective
The analysis was taken from the perspective of Mexican publicly
funded health care system. In the base-case analysis, the time
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were discounted at a rate of 5% annually [41].
Incremental Cost-Effectiveness Ratio
In this analysis, both the costs and the health consequences of the
alternatives were examined. The effectiveness measure was QALY.
The direct comparison between two alternatives was obtained
through the incremental cost-effectiveness ratio (ICER). Comparing
strategy SIR with strategy TAC, the ICER value represents the
relative increment of cost at which a relative unitary increment of
benefit could be obtained. The ICER was calculated as follows:
DC=DE¼
Xn
i¼1
DCi=
Xn
i¼1
DEi
whereDC
Fig
org¼ Costs of SIR  costs of TAC
¼ QALY gained with SIR – QALY gained with TACDE
To determine the relative threshold at which treatment
became cost-effective, we adopted a willingness-to-pay threshold
of 1 GDP per capita per QALY gained as ‘‘cost-effective’’ according
to the Mexican Guideline for economic evaluation [41]. The GDP
for Mexico in 2011 was US $ 10,064 resulting in the threshold of
US $10,064. Although this is lower than the 3 GDP per capita as
recommended by the WHO per unit of DALY averted [42] as a readily
available indicator to derive the following three categories of cost-
effectiveness: Highly cost-effective (less than GDP per capita); Cost-
effective (between one and three times GDP per capita); and Not
cost-effective (more than three times GDP per capita).
Sensitivity Analysis
Probabilistic sensitivity analysis (PSA) was performed by using Monte
Carlo simulation to evaluate the multivariate uncertainty in the
model. The input parameters were varied simultaneously over
specified ranges. Various probability distributions were chosen on
the basis of assumptions for each input parameter. The beta
distribution was specified for the probability, utility, and risk reduc-
tion parameters. The gamma distribution was specified for the cost
parameters. The Monte Carlo simulation drew values for each input
parameter and calculated expected cost and effectiveness for each-40,000
-30,000
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-10,000
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. 2 – Scatter plot of 1000 incremental cost and incremental Q
an rejection in renal transplant recipients. QALY, quality-adarm of the model. This process was repeated 1000 times to give a
range of all expected cost and effectiveness values.
To evaluate uncertainty with respect to model parameters, PSAs
with 1000 iterations were conducted for the key parameters for which
the greatest uncertainty existed. Therefore, the curve represents the
probability that SIR is cost-effective (compared with TAC) at particular
cost per QALY thresholds; hence, the term ‘‘acceptability curve.’’
In addition, univariate sensitivity analysis was conducted to
identify variables that had the largest impact on the model results.
For the univariate sensitivity analysis, we varied all parameters
shown in Table 2 by 10%. The parameters that had the largest
impact on the model results are presented in a tornado diagram.Analysis
Because our aim was to inform decision makers on the cost-
effectiveness of these two approaches of ESRD treatment, we
adopted this perspective to perform analyses. We used QALY
as an effectiveness measure.
The comparative efficiencies of alternative treatment strate-
gies were measured by the ICER, defined as the additional cost
of a specific treatment strategy divided by its additional health
benefit, expressed as QALYs gained. If one strategy was more
costly and less effective than another strategy, it was considered
to be strongly dominated. If a strategy was both less effective and
had a higher cost-effectiveness ratio than another strategy, it was
considered to be weakly dominated.Results
Table 3 presents the base-case cost-effectiveness results. As shown,
the total cost for the SIR treatment arm over the 20-year duration of
the model was estimated to be $136,778. This compares with
$142,624 for the TAC treatment arm, resulting in an incremental
cost of SIR compared with that of TAC of $5,846. Over 20 years,
SIR was estimated to have 8.18 QALYs compared with 7.33 QALYs
for TAC. The resulting incremental utility of SIR compared with
that of TAC is 0.84 QALY gained. The base case showed that the
least costly and more effective strategy was SIR. SIR strategy
had an ICER of $6940 per QALY gained ($/QALY).1.00 1.50 2.00 2.50
ALY for sirolimus versus tacrolimus in the prophylaxis of
justed life-year.
Table 2 – Model variables [9,35,36,38,40].
Name Probabilistic Deterministic SD Distribution Alpha Beta N
Probabilities
Probability of functioning
Transplant no events 0.41 0.41 0.01 Beta 1991 2902 4893
Probability of delayed
Graft function 0.28 0.27 0.01 Beta 1320 3573 4893
Probability of acute
rejection 0.38 0.37 0.01 Beta 1824 3069 4893
Probability of graft loss
Post-acute rejection 0.10 0.09 0.00 Beta 430 4463 4893
Probability of infection 0.16 0.15 0.01 Beta 742 4151 4893
Probability of malignancy
Post-transplant 0.02 0.02 0.00 Beta 114 4779 4893
Baseline annual
mortality risk
tpFuntional2Death 0.02 0.03 0.02 Beta 3.11 96.89 100
tpFails2Death 0.06 0.05 0.02 Beta 5.23 94.77 100
tpDialysis2Detah 0.10 0.10 0.03 Beta 10.23 89.77 100
Absolute risk reduction
rrcicloSIR 0.18 0.24 0.04 24.00 76.00 100
rrTraco 0.13 0.13 0.03 13.00 87.00 100
Costs
cFunctioning 96890 78701 11805 Gamma 44.44 1770.78
cFail 54519 65946 9892 Gamma 44.44 1483.79
cDialysis 131795 123158 18474 Gamma 44.44 2771.06
Quality of life weights
(utilities)
Functioning 0.76 0.77 0.031 Beta 77.00 23.00 100.00
Fail 0.68 0.67 0.060 Beta 67.00 33.00 100.00
Dialysis 0.54 0.57 0.104 Beta 57.00 43.00 100.00
Discount rate
Cost DR 5.0%
Outcome DR 5.0%
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A PSA was performed including all variables in the model (see
Table 2). The ICER scatter plot of SIR to TAC is shown in Figure 2 for a
discount rate of 5%. Each dot represents one simulation. The ICER
estimates in the southeast quadrant make up 88% of the simulations0.00
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Fig. 3 – Acceptability curve representing the probability that sir
(TAC) for different values of WTP for a QALY. QALY, quality-adjuand indicate that SIR is less costly and more effective, dominating
TAC. The rest of the simulations lie in the northeast quadrant, with
12% below US $10,064 per QALY. Results show that 100% of the
observations are cost-effective for a willingness-to-pay threshold of
$10,064 (1 GDP) per QALY. PSAs confirmed that the SIR strategy was
dominant over TAC in more than 88% of the cases.$30,000 $40,000 $50,000
eiling ratio
TAC
SIR
olimus (SIR) is cost-effective in comparison to tacrolimus
sted life-year; WTP, willingness to pay.
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Fig. 4 – Tornado diagram of the univariate sensitivity analysis showing the impact of individual input parameters on the
ICER per QALY. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SIR, sirolimus; TAC, tacrolimus.
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ability of SIR being cost-effective compared with TAC in a wide
range of willingness-to-pay thresholds (Figure 3). Before consid-
ering a discount rate of 5%, at a willingness-to-pay threshold of
$10,064 per QALY (corresponding to Mexico’s GDP for 2011), the
SIR strategy had 100% probability of being cost saving.
Univariate sensitivity analyses are summarized in Figure 4 as
a tornado diagram showing the cost savings of SIR resulting from
changes in different model parameters. The base case with an
ICER of – $6940 per QALY is represented by the central axis. For
all these variations, cost savings were seen with the SIR regime
(range of cost savings is $8822 to $5058).
Over 20 years of follow-up, there was evidence that SIR
patients had significantly less mortality rate, more QALY gained,
and less dialysis procedures than TAC arm patients (Fig. 5A–D).
The estimated cumulative medical costs at 20 years averaged
$136,778 for the SIR arm and $142,624 for the TAC arm (Fig. 5D).
As shown in Figure 5D, costs for TAC increased at a faster rate
because of crossover to dialysis therapy.Discussions
ESRD has a profound financial impact on patients, families, and
society as a whole. Most health care systems currently place great
importance not only on the efficacy of an intervention but also on its
cost. Cost-effectiveness analyses are becoming increasingly impor-
tant to allow patients, physicians, and payers to evaluate trade-offs
between clinical efficacy and financial impacts.
Diabetes is considered to be the leading cause of ESRD in Mexico
[43–45]. There are about 175,729 persons in Mexico with type 2
diabetes and nephropathy (urine albumin/creatinine4 300 mg/g)
[3,46]. Accordingly, the Latin American Society of Nephrology and
Hypertension Annual Report 2002 showed a prevalence of dialysis
(both hemodialysis and peritoneal dialysis) and renal transplant of
305 and 72 patients per million population in Mexico, respectively
[4,46], that is, a total national renal replacement therapy (RRT)
prevalence of 377 per million population. In the same report, anTable 3 – Average and incremental cost-effectiveness ratios of
Strategy Mean cost Incremental cost
Tacro´limus $ 142,624
Siro´limus $ 136,778 $ 5,846acceptance rate of 103 new patients for RRT per million population
was reported. These data reflect the limited availability of RRT and
the presence of data subregistry in Mexico.
The implications of this study are that SIR should be used
preferentially over TAC in subjects who receive a graft following
renal failure. As a result, long-term costs are likely to be notably
reduced and graft survival and quality of life improved substan-
tially. With limited clinical and economic resources and the
magnitude of costs for dialysis and posttransplantation care,
the relationship between cost and efficacy (short-term acute
rejection and long-term graft survival) of SIR becomes even more
important for decision makers to consider.
This study provides evidence for the preferential use of SIR
rather than TAC for the primary prevention of graft rejection in
patients undergoing RRT in Mexico. The magnitude of dominance
of SIR over TAC in Mexico suggests that these estimates are likely
to be reflected in analyses elsewhere. A study done in the United
Kingdom suggests that SIR may be more cost-effective than TAC
for the primary prevention of graft rejection in renal transplant
recipients. In this study, SIR was economically ‘‘dominant’’ [47].
SIR reduced acute rejection rates significantly [48,49]. The Rapa-
mune Maintenance Regimen study has demonstrated improved
renal function and blood pressure among kidney transplant patients
who had CsA withdrawn early after transplantation [22,50,51].
Despite the growing importance of economic evaluation in
informed decision making, few studies have been published to date
regarding the economic impact of the different therapeutic strate-
gies for the prophylaxis of graft rejection [52,53]. In fact, this study is
the first to be published in Mexico that assesses the economic value
for the Mexican Heal Care System of SIR among kidney transplant
patients who had CsA withdrawn early after transplantation.
Over 20 years, SIR was estimated to have 8.18 QALYs com-
pared to 7.33 QALY for TAC. The resulting incremental utility of
SIR compared to TAC is 0.84 QALY gained. SIR is estimated to be
both less costly and more effective than TAC, indicating that it is
the dominant strategy. Notably, results suggest that SIR has a 78%
probability of being dominant over the TAC strategy, and a 96%
probability of having an incremental cost-effectiveness ratio at orSiro´limus vs Tacro´limus.
Mean effect Incremental effect ICERs:
7.33
8.18 0.84 $ 6,940
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tive interventions based on the suggestions from the Commis-
sion on Macroeconomics and Health (CMH) (WHO 2001), states
that to be considered cost-effective, an intervention has to have a
cost-effectiveness ratio of less than three times gross domestic
product (GDP) per capita,. However, The WHO also delineates
three cost effectiveness thresholds; (i) highly cost effective,
defined as lower than the GDP per capita, (ii) cost-effective,
defined as one to three times GDP, and (iii) not-cost effective,
defined as more than three times the GDP. The GDP for Mexico in
2011 was US $10,064 resulting in the threshold of US $10,064, US
$10,064–US $30,192 and 4US $30,192 for the three categories,
respectively. Applying the WHO criteria, SIR would be considered
as an highly cost-effective intervention [53].
The analysis indicates that treatment with SIR is cost saving
compared with TAC treatment. Patients treated with SIR are
expected to see a significant improvement in life years and
QALYs. Patients treated with SIR are also expected to see a
reduction in dialysis procedures and mortality compared with
patients treated with TAC. The reduction in expected life years
and QALYs for TAC compared with SIR treatment was driven by
the higher expected dialysis and mortality rate. Overall, patients
receiving SIR were expected to receive the greatest benefit in
terms of both graft loss prevention and dialysis.
Limitations
The absence of both long-term outcome and quality of life from
trial data makes assessment of the clinical effectiveness and
cost-effectiveness of the newer immunosuppressants contingent
on modeling based on extrapolations from short-term trial out-
comes. The choice of the most appropriate short-term outcome
(e.g., acute rejection rate or measures of graft function) for such
modeling remains a matter of clinical and scientific debate.Conclusions
This modeling study demonstrates that prophylaxis treatment
with SIR in graft rejection in the Mexican setting is likely to be
viewed as good value for money over patient lifetimes. There
were benefits in terms of both projected life expectancy and
quality-adjusted life expectancy accompanied by cost savings
from dialysis avoided and increased treatment and overall total
lifetime costs.
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